Atezolizumab and bevacizumab

DRUG4 trials

Conditions

CancerHepatocellular CarcinomaNeoplasiaNeoplasmResectable Hepatocellular CarcinomaTumorshepatocellular carcinoma hepatocellular carcinoma

Phase 2

The Drug Rediscovery Protocol (DRUP Trial)

RecruitingNCT02925234

The Netherlands Cancer InstituteCancer, Neoplasia, Neoplasm +1

Start: 2016-08-31End: 2027-12-31Target: 1550Updated: 2024-01-24

Atezo+Bev study for pretreated patients

Active, not recruitingJPRN-jRCT1041200068

Yamashita Tatsuyahepatocellular carcinoma hepatocellular carcinoma

Start: 2020-11-26Target: 28Updated: 2026-06-29

LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

TerminatedNCT05537402

University of Texas Southwestern Medical CenterHepatocellular Carcinoma

Start: 2023-09-27End: 2025-06-06Updated: 2026-06-18

Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

RecruitingNCT07018947

Fundacion Clinic per a la Recerca BiomédicaResectable Hepatocellular Carcinoma

Start: 2026-06-02End: 2031-06-01Target: 90Updated: 2026-07-08

Nature2026-04-151 citations

The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).

2025-01-073 citations

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

Clinical Cancer Research2024-07-184 citations

Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol

Clinical Cancer Research2024-06-272 citations

Efficacy and safety of olaparib in patients with tumors harboring alterations in homologous recombination repair pathway associated genes: Results from the Drug Rediscovery Protocol.

Journal of Clinical Oncology2024-06-013 citations

The pathway alteration load as a pan-cancer determinant of outcome of targeted therapies: Results from the Drug Rediscovery Protocol (DRUP).

Journal of Clinical Oncology2024-06-01

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol

Clinical Cancer Research2024-04-173 citations

Phase II study of atezolizumab and bevacizumab combination therapy for patients with advanced hepatocellular carcinoma who previously received systemic treatment.

Journal of Clinical Oncology2024-01-202 citations

Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.

Journal of Clinical Oncology2023-06-013 citations

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.

2023-03-0410 citations

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

BMC Cancer2023-02-2223 citations

Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study

BMC Medical Genomics2022-11-046 citations

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.

2022-05-226 citations

First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling.

Journal of Clinical Oncology2022-02-162 citations

Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.

2022-01-2536 citations

Olaparib monotherapy in pretreated patients with <i>BRCA1/2</i> alterations: Results of a DRUP trial cohort.

Journal of Clinical Oncology2020-05-201 citations

Afatinib as a novel potential treatment option for <i>NRG1</i> fusion-positive tumors.

Journal of Global Oncology2019-10-076 citations

Update on the Drug Rediscovery Protocol: Expanded use of existing anticancer drugs in patients with a known molecular profile.

Journal of Clinical Oncology2019-05-20

The Drug Rediscovery Protocol (DRUP).

Journal of Clinical Oncology2017-05-203 citations

Atezolizumab and bevacizumab

Sponsors

Conditions

Phase 2

Related Papers